Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 GeneticVariation disease BEFREE Women diagnosed with breast cancer between 2006 and 2015 and treated with tamoxifen or aromatase inhibitors (n = 36,472) were stratified according to low (without osteoporosis diagnosis nor bisphosphonates exposure) or high (with osteoporosis and/or treated with bisphosphonates) fracture risk. 31596961 2020
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 Biomarker disease BEFREE In multivariable analyses, osteoporosis was positively associated with the aromatase inhibitor (AI) sequential treatment after tamoxifen (HR, 3.14; 95% CI, 1.44-6.88; P = .004) but was more pronounced with AI use as upfront monotherapy (HR, 5.53; 95% CI, 1.46-20.88; P = .012). 30413856 2019
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 Biomarker disease BEFREE Osteoporosis is a major side effect of aromatase inhibitors (AIs), which are greatly effective in the treatment of breast cancer. 31393399 2019
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 GeneticVariation disease BEFREE The osteoporosis incidence in postmenopausal patients on aromatase inhibitors (AI) is much higher than in those on tamoxifen, and adverse effects other than musculoskeletal disorders are less on AI than on tamoxifen. 31172521 2019
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 Biomarker disease BEFREE Osteoporosis (OP) risk factor assessment and bone mineral density (BMD) testing are frequently omitted at baseline in aromatase inhibitor (AI) studies, which may lead to misinterpretation of AI associated bone loss. 30939140 2019
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 Biomarker disease BEFREE In postmenopausal women with hormone receptor-positive, early-stage breast cancer, treatment with adjuvant aromatase inhibitors is the standard of care, but it increases risk for osteoporosis and fractures. 30795951 2019
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 GeneticVariation disease BEFREE The analysis of the CYP19A1 rs700518 polymorphism showed that heterozygotes were more common in the group with osteoporosis (58.3%) than in the control group (52.8%). 30855728 2019
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 GeneticVariation disease BEFREE Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer. 29520506 2019
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 Biomarker disease BEFREE A secondary osteoporosis associated with the VFC was diagnosed in 52 patients: glucocorticoid-induced osteoporosis (25.7%), non-malignant hemopathies (6.2%), alcoholism (4.4%), use of aromatase inhibitors (3.6%), primary hyperparathyroidism (2.7%), hypercorticism (2.7%), anorexia nervosa (2.7%), and pregnancy and lactation-associated osteoporosis (1.8%). 30519756 2019
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 AlteredExpression disease BEFREE The women with lower aromatase activity may have greater likelihood of PMOP and the E<sub>2</sub>/T was expected to be a valuable indicator for the prediction of PMOP and to monitor the process of osteoporosis. 29329467 2018
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 GeneticVariation disease BEFREE For women with breast cancer, bone mineral density screening is recommended with long-term aromatase inhibitor use because of the risk of osteoporosis due to estrogen deficiency. 29794680 2018
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 GeneticVariation disease BEFREE Osteoporosis treatment, including vitamin D and bisphosphonates, is associated with a 50% reduction of relapse and death in women treated with aromatase inhibitors for ER+ breast cancer. 30036740 2018
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 Biomarker disease BEFREE Other selected articles cover effectiveness of bisphosphonates and changes in mineralization after long-term use, new guidelines for glucocorticoid- and aromatase inhibitor-induced osteoporosis, increasing use of high-dose vitamin D supplements despite lack of evidence for their widespread high-dose use, and cardiovascular safety concerns surrounding the use of calcium supplements. 29546647 2018
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 Biomarker disease BEFREE The aim of this study was to evaluate the effects of denosumab in patients with osteoporosis (OP) and non-metastatic breast cancer following treatment of 1) surgery, 2) surgery and aromatase inhibitors, and 3) surgery, aromatase inhibitors, and anti-cancer agents, compared with those in primary OP patients. 29559791 2018
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 GeneticVariation disease BEFREE For women with breast cancer, bone mineral density screening is recommended with long-term aromatase inhibitor use because of the risk of osteoporosis due to estrogen deficiency. 29794673 2018
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 GeneticVariation disease BEFREE It is well known that anti-estrogen therapy (AET), especially aromatase inhibitors (AI), is associated with rapid bone loss and thus increases the risk of osteoporosis. 29981903 2018
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 Biomarker disease BEFREE Research on the mechanism of Bushen Jianpi decoction (BJD) for preventing and treating osteoporosis caused by aromatase inhibitors (AI) during treatment for breast cancer resection. 27983533 2017
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 GeneticVariation disease BEFREE Breast cancer patients in the MA.27 trial had similar outcomes with steroidal aromatase inhibitor (AI) exemestane and nonsteroidal anastrozole.AIs increase the risk of osteoporosis. 28464211 2017
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 Biomarker disease BEFREE Age, breast cancer history, prior chemotherapy, and tamoxifen or aromatase inhibitor (AI) use were not associated with having osteoporosis or osteopenia. 26086567 2015
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 Biomarker disease BEFREE Despite their effectiveness in reducing tumor recurrence, aromatase inhibitors have adverse effects on the cardiovascular system and increase osteoporosis and bone fractures. 25023195 2014
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 GeneticVariation disease BEFREE In conclusion, CYP17 and CYP19 gene polymorphisms were found to be associated with osteoporosis in postmenopausal women in Turkey. 21948762 2011
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 Biomarker disease CTD_human Dysfunction of the enzyme aromatase (CYP19) is associated with endocrine pathologies such as osteoporosis, impaired fertility and development of hormone-dependent cancers. 20723554 2010
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 AlteredExpression disease BEFREE In addition to augmenting the ability of AIs to inhibit BCa growth, calcitriol acting as a selective aromatase modulator that increases aromatase expression in bone would reduce the estrogen deprivation in bone caused by the AIs, thus ameliorating the AI-induced side effect of osteoporosis. 19906814 2010
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 GeneticVariation disease LHGDN Thus, aromatase is an attractive osteoporosis candidate gene. 17391072 2007
CUI: C0029456
Disease: Osteoporosis
Osteoporosis
0.500 Biomarker disease BEFREE Thus, aromatase is an attractive osteoporosis candidate gene. 17391072 2007